Alaunos Therapeutics, Inc. TCRT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Alaunos Therapeutics, Inc. (TCRT) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $3000 and net income of -$4M, a net margin of -133666.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -177%.
About Alaunos Therapeutics
Alaunos Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $7M in 2016 to $5000 in 2025, a decline of about 55.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 35% over three years (dilution for shareholders). It spends 27260% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3000 | $5000 | $10000 | $5000 | $3M | $398000 | $0 | — | $146000 | $16M | $7M |
| Net income | -$4M | -$4M | -$5M | -$5M | -$38M | -$79M | -$80M | -$118M | -$53M | -$54M | -$165M |
| Free cash flow | — | -$3M | -$5M | -$30M | -$29M | -$65M | -$67M | -$41M | -$50M | -$55M | -$59M |
| EPS (diluted) | $-1.91 | $-2.20 | $-2.92 | $-21.97 | $-26.10 | $-55.50 | $-57.00 | $-105.00 | $144.00 | $-79.50 | $-198.00 |
| Net margin | -133666.7% | -83520.0% | -46790.0% | -93580.0% | -1291.2% | -19786.7% | — | — | -36381.5% | -341.7% | -2409.2% |
| ROIC | — | -155.0% | -184.3% | -429.2% | -47.8% | -70.1% | -49.3% | -46.9% | -49.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Alaunos Therapeutics pay a dividend?
Not currently.
Is Alaunos Therapeutics a good stock to buy?
We do not give buy or sell advice. Alaunos Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.